WFDC2 and ablepharon macrostomia syndrome: Our findings demonstrate that the ADNEX model consistently outperforms ROMA, RMI I–IV, CA125, and HE4 in terms of its ability to accurately discriminate between malignant and benign adnexal masses (AMs).